Taken together, our study identified a novel and potential therapeutic strategy by combined inhibition of BRD4-RAC1 signaling to suppress breast cancer development and tumorigenesis via c-MYC/G9a/FTH1 axis and down regulation of HDCA1 in different molecular subtypes in a context-dependent manner. This evidence concerns the gene MYC and breast carcinoma.